Summary sheet
The present project represents the first operation with Chiesi Farmaceutici and is aimed at assisting the construction of a new R&D centre as well as the upgrade of the equipment, allowing the rationalization of Chiesi's R&D activities and their future development.
Chiesi is one of the leading pharmaceutical companies in Italy. Although being a mid-sized privately owned group, Chiesi invests every year a significant portion of total turnover (13% in 2004) in R&D. The investments will strengthen the regional and local endowment of R&D and contribute to the EU's private sector investments in R&D, in line with the Bank's i2i plan concerning the promotion and strengthening of scientific research.
To be verified during appraisal.
To be verified during appraisal.
Research & Development
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications